# US 2008/0306113 A1 · Methods for treating macular degeneration using 4-(amino)-2-(2,6-dioxo(3-piperidyle))-isoindoline-1,3-dione

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306113 A1
- Document ID: US20080306113A1
- Status: Published application
- Kind: A1
- Application number: 12/148,795
- Filed: 2008-04-22
- Published: 2008-12-11
- Earliest claimed: 2000-11-30
- Inventors: Anthony Treston; Jamshed H. Shah; Robert J. D'Amato; Kimberly A. Hunsucker; John Rougas; Barry P. Conner; Victor Pribdula; Glenn M. Swartz
- Web page: https://patentgrep.com/patent/US20080306113A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/10: for accommodation disorders, e.g. myopia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/22: for herpes viruses
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/02: Immunomodulators
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, alone or in combination with a second active agent and/or surgery.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method of treating macular degeneration, which comprises administering to a patient having macular degeneration a therapeutically effective amount of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione of the formula:
or an enantiomer thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the compound is 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione.

### Claim 19 (depends on 17)

The method of claim 17, wherein the enantiomer is an enantiomerically pure R isomer.

### Claim 20 (depends on 17)

The method of claim 17, wherein the enantiomer is an enantiomerically pure S isomer.

### Claim 21 (depends on 17)

The method of claim 17, wherein the compound is administered orally.

### Claim 22 (depends on 21)

The method of claim 21, wherein the compound is administered in the form of a capsule or tablet.

### Claim 23 (depends on 17)

The method of claim 17, wherein the compound is administered in an amount of from about 0.1 to about 300 mg/kg per day.

### Claim 24 (depends on 23)

The method of claim 23, wherein the compound is administered in an amount of from about 0.5 to about 50 mg/kg per day.

### Claim 25 (depends on 23)

The method of claim 23, wherein the compound is administered in an amount of from about 0.1 to about 2 mg/kg per day.

### Claim 26 (depends on 17)

The method of claim 17, wherein the compound is administered orally, opthalmically, parenterally, transdermally, mucosally, nasally, buccally, rectally, sublingually, topically or vaginally.

### Claim 27 (depends on 17)

The method of claim 17, wherein the compound is administered in the form of a cream, a lotion, an ointment, a patch, a gel, a paste, a liquid, a solution, an emulsion, a suspension, a dispersion, a spray, or a drop.
